Colinz Laboratories Fair Value
Colinz Laboratories (COLINZ) average fair value is ₹68.18 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹44.19 (+54.29%), fair value range ₹25.21–₹188.04. Also explore COLINZ share price charts to track price trends across different timeframes.
Fair Value Analysis Export
COLINZ Fair Value vs Current Price — Valuation Summary
COLINZ average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit COLINZ screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
COLINZ Fair Value Analysis — Data Sources & Coverage
Colinz Laboratories financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. See COLINZ price to book ratio to compare market price against book value per share.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
COLINZ vs Healthcare Sector Peers — P/E, P/B & Market Cap
Colinz Laboratories P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| KRM Ayurveda | KRMAYURVED | - | 4.07 | ₹508 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.